PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma

Clinical trial NCT06125223 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06125223
Sponsor: Xijing Hospital
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Squamous Cell Carcinoma of Head and Neck Neoadjuvant Therapy Immunotherapy

Start date: 2023-11-01
Primary completion: 2025-11-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.